Dr. Reddy's acquired the Eton portfolio for an upfront payment of approximately USD 5 million in cash, plus contingent payments of up to USD 45 million.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated June 22, 2022.
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4960 in its research report dated June 22, 2022.
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated June 22, 2022.
"We are pleased to launch this important generic product, illustrating our continued commitment to bring affordable generic medicines to market for patients," Dr Reddy's Laboratories Inc North America Generics CEO Marc Kikuchi said in a statement.
After a short-term correction, Dr Reddy's Laboratories has formed higher bottom reversal formation. The stock is consistently taking support near the 50 and 20 day SMA (Rs 4,192, Rs 4,227)
Olema and Aurigene Discovery Technologies, a wholly-owned unit of Dr Reddy's Laboratories, have inked an exclusive global licence agreement in this regard.
KR Choksey is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5261 in its research report dated May 23, 2022.
Prabhudas Lilladher is bullish on Dr. Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4900 in its research report dated May 20, 2022.
ICICI Direct is bullish on Dr Reddy's Laboratories has recommended buy rating on the stock with a target price of Rs 4800 in its research report dated May 20, 2022.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated May 19, 2022.
The company reported a 15 percent year-on-year rise in consolidated revenues from operations to Rs 5,437 crore for the March quarter.
Under the partnership, HK inno.N Corporation will be responsible for the manufacture and supply of Tegoprazan, while Dr Reddy’s will be responsible for local clinical development, registration, marketing and sales in the licensed territories.
Sharekhan is bullish on Dr. Reddy’s Laboratories has recommended buy rating on the stock with a target price of Rs 5550 in its research report dated April 12, 2022.
On Thursday, Zee Entertainment opened with a gap up and gained over 15 percent. In this month so far, it rallied over 34 percent. The important thing is, after a long time it succeeded to close above 200 & 50 day SMA (simple moving average).
The share touched a 52-week high of Rs 5,613.65 and a 52-week low of Rs 4,135.90 on 07 July, 2021 and 19 March, 2021.
As per the terms of the definitive agreement executed between the companies, Mankind Pharma will take over the manufacturing, marketing and distribution of both the products in India.
Tweeting the news out on February 6, the Health Minister said that this is India's ninth COVID-19 vaccine in the country.
ICICI Direct is bullish on Dr Reddys Laboratories has recommended buy rating on the stock with a target price of Rs 5160 in its research report dated January 29, 2021.
Addressing a press conference after announcing the company’s Q3 results, a senior executive of the drug maker said Phase 3 clinical trial data of Russia’s single dose COVID-19 vaccine Sputnik Light has been submitted to the regulator and is awaiting approval.
Molnupiravir is an orally administered form of a potent ribonucleoside analog that inhibits the replication of SARS‐CoV‐2